This Biotech Inventory Is Up 50% in 2025, However Redditors Say It Has Extra Upside – Right here’s Why

We lately printed 10 Finest Small-Cap Shares With Big Potential Based on Reddit as Market Appears Past AI Commerce. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the many greatest small-cap shares to purchase in keeping with Redditors.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the greatest small-cap shares with enormous upside potential in keeping with Redditors. The corporate is engaged on oncology therapies designed to focus on the tumor microenvironment. The corporate lately introduced to accumulate Elektrofi, which may broaden its drug supply capabilities into high-concentration biologic formulations. The inventory has gained about 54% to date this yr.

The FDA lately accredited Darzalex Faspro, an injectable model of the a number of myeloma remedy daratumumab, developed by J&J and Halozyme Therapeutics (HALO). The product was accredited as a front-line possibility for mild chain (AL) amyloidosis, a uncommon blood cell dysfunction.

Earlier in November, the corporate posted sturdy quarterly outcomes, indicating income development of twenty-two% yr over yr, whereas royalty income elevated 52%.

Artisan Small Cap Fund acknowledged the next relating to Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its second quarter 2025 investor letter:

“Among the many detractors in Q2 have been Halozyme Therapeutics, Inc. (NASDAQ:HALO), Clearwater Analytics and Lattice Semiconductor. Halozyme offers a novel expertise platform (ENHANZE®) that converts biologics and small molecule medicine administered intravenously right into a subcutaneous formulation. The corporate reported sturdy earnings and raised its full-year steerage in Might, however shares have been negatively impacted by uncertainty surrounding new draft steerage from the Facilities for Medicare and Medicaid Companies (CMS) on drug pricing and potential delays in launching new merchandise. We trimmed our place as we await ultimate steerage from CMS.”

Whereas we acknowledge the potential of HALO as an funding, our conviction lies within the perception that some AI shares maintain higher promise for delivering increased returns and have restricted draw back threat. If you’re in search of a particularly low-cost AI inventory that can also be a significant beneficiary of Trump tariffs and onshoring, see our free report on the greatest short-term AI inventory.

Disclosure: None. This text is initially printed at Insider Monkey.